Tone får en del tyn, noe av det synes jeg blir urimelig. Hun er i en svært utsatt stilling der toleransen for å si noe feil er så godt som null.
Nylig artikkel om copanlisib, som nylig fikk accelerated approval i samme indikasjon som Betalutin blir rettet mot først. Helt ærlig synes jeg fremdeles Betalutin virker overlegent med det vi vet så langt:
http://www.ascopost.com/issues/december-25-2017/another-pi3k-inhibitor-welcome-for-use-in-indolent-lymphoma/
"It will be interesting to see whether the intravenous schedule seen with copanlisib is viewed as favorable or unfavorable in the eyes of practitioners and patients. Receiving treatments on days 1, 8, and 15 of every 28-day cycle is certainly tolerable for a few months of therapy, but the copanlisib therapy is designed to be given indefinitely, and this administration schedule may become cumbersome over time. That said, having another agent available for patients with relapsed indolent lymphoma is certainly welcome. "
"Efficacy evaluation demonstrated an objective response rate of 59%, with 12% of the patients achieving a complete response. The median duration of response was 22 months, and the median progression-free survival was 11 months. Among the patients with follicular lymphoma, the response rate was 59%, with a complete response in 14%, and the median response duration was 12.2 months. "